Related Experiment Video
Updated: Jul 15, 2026
09:58
Lipidomics and Transcriptomics in Neurological Diseases
Published on: March 18, 2022
Reprogramming lipid metabolism for cognitive restoration in Alzheimer's via PLA2G4E
Sara Badesso1,2, María Espelosín1,2, Cristina Alonso3
1Gene Therapy for CNS Disorders Program, Center for Applied Medical Research (CIMA) University of Navarra Pamplona Spain.
Alzheimer'S & Dementia (New York, N. Y.)
|July 13, 2026
Summary
Restoring lipid metabolism with PLA2G4E gene therapy improved memory and cognitive function in Alzheimer's disease (AD) models. This approach offers a new therapeutic strategy by targeting brain lipid pathways for synaptic and cognitive rescue.
Area of Science:
- Neuroscience
- Biochemistry
- Genetics
Background:
- Dysregulated brain lipid metabolism is increasingly linked to Alzheimer's disease (AD) pathogenesis.
- Lipid pathways influence key AD pathologies including neuroinflammation and protein aggregation.
- Targeting lipid metabolism presents a promising, yet largely unexplored, therapeutic avenue for AD.
Purpose of the Study:
- To investigate the therapeutic potential of Phospholipase A2 Group IVE (PLA2G4E) in Alzheimer's disease.
- To validate PLA2G4E as a therapeutic target using a gene-delivery approach in an AD mouse model.
Main Methods:
- Adeno-associated virus (AAV) vector (AAVP31) was used for gene delivery of PLA2G4E in the APP NL-G-F AD mouse model.
- Widespread brain expression of PLA2G4E was achieved via a blood-brain barrier-penetrant AAV vector.
- Brain lipidomics was employed to elucidate treatment mechanisms.
Main Results:
- PLA2G4E expression successfully rescued memory deficits and improved cognitive performance in AD models.
- Treatment led to reduced tau phosphorylation and enhanced brain glucose metabolism.
- Observed effects correlated with partial normalization of altered lipid metabolism in the brain.
Conclusions:
- PLA2G4E demonstrates significant therapeutic potential for Alzheimer's disease.
- Modulating lipid metabolic pathways via PLA2G4E offers a novel strategy for synaptic and cognitive restoration in AD.
- These findings provide mechanistic insights into the link between lipid metabolism and AD pathology.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...